Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Black Diamond Therapeutics, Inc.

Market Cap 100M 86.61M 79.81M 74.71M 140M 9.53B 142M 942M 367M 4.64B 376M 368M 16.06B P/E Ratio 2026 *
-2.7x
P/E Ratio 2027 * -1.74x
Enterprise Value 100M 86.61M 79.81M 74.71M 140M 9.53B 142M 942M 367M 4.64B 376M 368M 16.06B EV / Sales 2026 *
18.1x
EV / Sales 2027 * -
Free-Float
99.38%
Yield 2026 *
-
Yield 2027 * -
1 day-3.85%
1 week-11.17%
Current month-21.17%
1 month-38.81%
3 months-17.45%
6 months-37.28%
Current year-27.98%
1 week 1.74
Extreme 1.745
2.01
1 month 1.74
Extreme 1.745
3.97
Current year 1.74
Extreme 1.745
3.97
1 year 1.74
Extreme 1.745
4.94
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
13.1
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 51 11/08/2021
Chief Executive Officer 62 16/09/2023
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap.
03-20
NEA Management Co. LLC
OtherCompany 0 0%
03-20Free

Director

6,105 0.0107%
03-20Free

Director

6,919 0.0121%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%-11.17%-24.24%-19.35% 100M
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +1.23%+0.76%+22.53%+92.67% 21.38B
Weighted average by Cap. +1.72%+2.36%+32.01%+99.54%

Financials

2026 *2027 *
Net sales 5.56M 4.8M 4.42M 4.14M 7.76M 528M 7.88M 52.21M 20.36M 257M 20.85M 20.41M 890M -
Net income -40.47M -34.96M -32.21M -30.15M -56.51M -3.85B -57.38M -380M -148M -1.87B -152M -149M -6.48B -70.04M -60.5M -55.75M -52.18M -97.8M -6.66B -99.31M -658M -257M -3.24B -263M -257M -11.22B
Net Debt - -
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
12/06/26 1.750 $ -3.85% 2,312,876
11/06/26 1.820 $ -1.62% 1,446,066
10/06/26 1.850 $ -2.63% 1,549,705
09/06/26 1.900 $ +2.70% 1,719,949
08/06/26 1.850 $ -6.09% 1,114,102
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.750USD
Average target price
9.857USD
Spread / Average Target
+463.27%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BDTX Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!